Journal
PHARMACOLOGY
Volume 84, Issue 1, Pages 17-23Publisher
KARGER
DOI: 10.1159/000221379
Keywords
Lipoxin A(4); Hypoxia; Human endothelial cell; Hypoxia-inducible factor-1 alpha; Vascular endothelial growth factor
Categories
Funding
- Ministry of Education of China [200803430002]
Ask authors/readers for more resources
Lipoxin A(4) (LXA(4)), a 'stop signal' for inflammation, is endogenously produced by eicosanoids, mainly via cell-to-cell interactions. At present, its influence on hypoxic angiogenesis, which is responsible for tumor growth and metastasis, has not been determined. Hypoxia regulates a variety of transcription factors including hypoxia-inducible factor (HIF)-1 alpha, which plays a role in the expression of vascular endothelial growth factor (VEGF) and is considered a target for anti-angiogenic therapy. In this study, we utilized cobalt chloride (CoCl 2) to mimic hypoxia in vitro. Data suggested that LXA(4) decreased the expression and nucleus translocation of HIF-1 alpha in a dose-dependent manner in CoCl2-treated human umbilical vein endothelial cells (HUVEC). Furthermore, we confirmed that LXA(4) suppressed VEGF expression, tube formation and migration activity of HUVEC under hypoxia induced by CoCl2. These results suggest that LXA(4) may have inhibitory effects on tumor angiogenesis through downregulation of the expression and nucleus translocation of HIF-1 alpha. In summary, this study provides the first evidence for the anti-angiogenic role of LXA(4) on hypoxic human endothelial cells, which may have therapeutic value for cancer and other angiogenesis-associated diseases. Copyright (C) 2009 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available